US2016015870A1PendingUtilityA1

Drug Composition and Coating

Assignee: GORE & ASSPriority: Mar 13, 2014Filed: Sep 14, 2015Published: Jan 21, 2016
Est. expiryMar 13, 2034(~7.6 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 9/00A61P 7/02A61L 31/08A61L 29/085A61L 2300/606A61K 31/727A61K 9/0024A61L 2300/216A61L 2300/42A61L 29/16A61L 27/34A61K 31/436A61L 33/0035A61L 33/08A61L 2300/608A61L 27/54A61L 33/0076A61L 33/04A61L 2300/416A61K 45/06A61L 29/08A61F 2002/91575A61F 2/915A61L 33/064A61L 31/048A61K 31/337A61L 2420/06A61L 31/16A61F 2/07A61L 2300/61A61L 2300/602A61L 31/10A61L 27/28A61L 2420/02A61L 31/06A61K 2300/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

Claims

exact text as granted — not AI-modified
1 . A medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization. 
     
     
         2 . A method for the prevention or treatment of stenosis or restenosis which comprises inserting transiently or permanently into said blood vessel in the human body a medical device according to  claim 1 .

Join the waitlist — get patent alerts

Track US2016015870A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.